Journal of Psoriasis and Psoriatic Arthritis最新文献

{"title":"Combining Clinical, Genetic and Protein Markers Using Machine Learning Models Discriminates Psoriatic Arthritis Patients From Those With Psoriasis.","authors":"Darshini Ganatra, Max Kotlyar, Amanda Dohey, Dianne Codner, Quan Li, Fatima Abji, Mozhgan Rasti, Lihi Eder, Dafna Gladman, Proton Rahman, Igor Jurisica, Vinod Chandran","doi":"10.1177/24755303251344134","DOIUrl":"10.1177/24755303251344134","url":null,"abstract":"<p><strong>Background: </strong>Psoriatic Arthritis (PsA), an immune mediated inflammatory arthritis, affects a quarter of patients with cutaneous psoriasis, usually after psoriasis onset. Early diagnosis of PsA is challenging. A biomarker-based diagnostic test may facilitate early diagnosis.</p><p><strong>Objectives: </strong>We aimed to determine whether specific clinical features or genetic and protein markers, alone or in combination, can distinguish patients with PsA from those with psoriasis without PsA (PsC).</p><p><strong>Methods: </strong>Patients with PsA and PsC were identified from a database of patients with psoriatic disease. Detailed demographic and clinical information were collected at time of assessment. Single-nucleotide polymorphisms (SNPs) of 19 \"PsA weighted\" genes were genotyped. Serum samples were used to assess 15 protein markers by ELISA. Association between clinical, genetic and protein markers and PsA were determined, and models were developed to discriminate PsA from PsC using machine learning algorithms.</p><p><strong>Results: </strong>Demographic and clinical information had low predictive value in distinguishing PsA from PsC (AUC - 0.607, <i>P</i> < .01). SNP and protein panels also had low value in discriminating PsA from PsC (AUC - 0.691, <i>P</i> < .001 and AUC - 0.694, <i>P</i> < .001, respectively). Combining protein, SNPs and clinical features provided better discriminatory value (best performing model: Random Forest, AUC - 0.733, <i>P</i> < .001).</p><p><strong>Conclusion: </strong>Combining previously identified clinical, genetic and protein markers have a fair ability to differentiate PsA from PsC. Further studies are required for identifying better diagnostic signatures.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"105-114"},"PeriodicalIF":0.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Association Between Systemic Treatments for Moderate to Severe Psoriasis and SARS-CoV-2 Infection Outcomes.","authors":"Rini Desai, Mehrtash Hashemzadeh, Liliana Tong, Rebecca Olsen, Mariana McCune, Chase Irwin, Mitchell Davis","doi":"10.1177/24755303251342996","DOIUrl":"10.1177/24755303251342996","url":null,"abstract":"<p><p>Moderate to severe psoriasis is often treated with systemic medications, including traditional therapies (eg, methotrexate, cyclosporine) and biologics (eg, TNF inhibitors, IL-17 and IL-23 inhibitors). These immunomodulating treatments raise concerns about infection risks, particularly during the SARS-CoV-2 pandemic. However, literature on systemic therapy and COVID-19 outcomes in the United States is limited. This retrospective cohort study analyzed adults with psoriasis and a primary SARS-CoV-2 diagnosis from the 2020 Health care Cost and Utilization Project National Inpatient Sample database. Patients were stratified by systemic medication use, and propensity score matching adjusted for baseline comorbidities. Logistic regression and bivariate analyses assessed the association between systemic therapy and clinical outcomes, including medications and procedures for COVID-19 treatment, length of stay, and mortality. 721,870 patients were included after propensity score matching. Patients receiving systemic medications had higher odds of requiring supplemental oxygen (OR = 1.30; <i>P</i> < .001) but lower odds of mechanical ventilation (OR = .76; <i>P</i> < .001) and intubation (OR = .78; <i>P</i> < .001). They also experienced shorter hospital stays (IRR = .982; <i>P</i> < .001) and lower mortality (OR = .74; <i>P</i> < .001). Systemic treatments for psoriasis influence COVID-19 outcomes, reducing the need for severe respiratory interventions, shortening hospitalization duration, and lowering mortality. These findings highlight the safety of systemic therapies, even during periods of heightened infection risk like the SARS-CoV-2 pandemic. Future research should investigate the differential effects of biologics and traditional therapies.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251342996"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study.","authors":"Camilla Mazzanti, Marino Paroli, Gianluca Santoboni, Olga Addimanda, Bernd Raffeiner, Alessandra Bezzi, Elisa Visalli, Eleonora Celletti, Antonella Farina, Simone Bernardi, Maddalena Larosa, Romina Andracco, Patrizia Del Medico, Aldo Biagio Colella Molica, Dilia Giuggioli, Federica Lumetti, Gilda Sandri, Marta Priora, Francesca Serale, Valeria Nucera, Francesca Ometto, Elena Bravi, Alberto Lo Gullo, Palma Scolieri, Simone Parisi, Viviana Ravagnani, Rosetta Vitetta, Antonio Marchetta, Andrea Becciolini, Claudio Angrisani, Massimiliano De Simone, Rosalba Caccavalle, Massimo Reta, Mirco Magnani, Fabio Mascella, Roberta Foti, Giorgio Amato, Francesco De Lucia, Ylenia Dal Bosco, Rosario Foti, Myriam Di Penta, Emanuela Sabatini, Pietro Del Biondo, Francesco Girelli, Dario Camellino, Gerolamo Bianchi, Natalia Mansueto, Gianluca Smerilli, Veronica Franchina, Carlo Salvarani, Aurora Ianniello, Cecilia Giampietro, Eleonora Di Donato, Daniele Santilli, Gianluca Lucchini, Eugenio Arrigoni, Ilaria Platè, Vincenzo Bruzzese, Enrico Fusaro, Maria Chiara Ditto, Davide Murgia, Guido Rovera, Alessandro Volpe, Giulio Ferrero, Giuditta Adorni, Francesco Colella Molica, Alarico Ariani","doi":"10.1177/24755303251342503","DOIUrl":"10.1177/24755303251342503","url":null,"abstract":"<p><p>IXE (Ixekizumab) is a monoclonal antibody targeting interleukin-17A (IL17A) which has demonstrated significant efficacy and safety in the management of psoriatic arthritis (PsA) in randomized controlled trials (RCTs). However, available data on long-term persistence of therapy are scarce.</p><p><strong>Methods: </strong>This multi-center study aimed to evaluate the drug retention rate (DRR) of IXE in a real-world setting and to identify key factors influencing treatment persistence. 195 patients with PsA treated with IXE between 2018 and 2024 were included. The primary outcome was DRR, calculated at 360, 720, and 1080 days after treatment initiation. Clinical and demographic factors were analyzed as potential predictors of IXE treatment permanency.</p><p><strong>Results: </strong>IXE retention rates were 66% at 360 days, 49% at 720 days, and 39% at 1080 days. Low baseline disease activity was a strong predictor of higher retention (HR 0.24, 95% CI: 0.09-0.62, <i>p</i> = 0.003), while younger age was significantly associated with improved persistence (HR 0.98, 95% CI: 0.96-1.00, <i>p</i> = 0.045). Conversely, patients with both axial and peripheral joint involvement were more likely to discontinue therapy (HR 1.78, 95% CI: 1.04-3.06, <i>p</i> = 0.036), as were those receiving IXE as a second- or third-line therapy (HR 1.17, 95% CI: 1.02-1.33, <i>p</i> = 0.021).</p><p><strong>Conclusions: </strong>This multicenter real-world study confirms the long-term retention rate of IXE in PsA. The findings highlight key factors influencing treatment persistence and provide valuable insights to optimize patient management. Further real-world research is needed to better understand the therapeutic performance of IXE in different patient populations.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"76-83"},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Psoriatic Arthritis Management From 1993 to 2019: Rise of Biologics and Decline of Oral Small Molecules.","authors":"Brad R Woodie, Sarayu Balachandar, Alan B Fleischer","doi":"10.1177/24755303251342501","DOIUrl":"10.1177/24755303251342501","url":null,"abstract":"<p><strong>Background: </strong>Traditional oral small molecule disease-modifying antirheumatic drugs (OSMs) have historically been the cornerstone of psoriatic arthritis (PsA) management. However, biologics have gained prominence due to their superior efficacy in patients with an inadequate response to OSMs.</p><p><strong>Objective: </strong>To analyze trends in the use of OSMs, biologics, and combination therapy for PsA management from 1993 to 2019.</p><p><strong>Methods: </strong>We utilized the National Ambulatory Medical Care Survey to examine PsA treatment patterns. Medications were classified as OSMs, biologics, or combination therapy (both an OSM and a biologic). Weighted Rao-Scott χ² tests and one-way ANOVA assessed differences in treatment patterns over time and by patient demographics.</p><p><strong>Results: </strong>Among an estimated 3.7 million visits for PsA (112 unweighted visits) where systemic therapy was prescribed, biologic use significantly increased (<i>P</i> = .006) over time, OSM use declined (<i>P</i> < .001), and combination therapy initially increased but later decreased (<i>P</i> < .001). There were no significant differences in treatment patterns by age, sex, race, ethnicity, or insurance status (all <i>P</i> > .2).</p><p><strong>Conclusions: </strong>Biologics have increasingly replaced traditional OSMs as the primary treatment for PsA. The decline in combination therapy after 2013 likely reflects the improved efficacy of newer biologics, reducing the need for adjunctive OSM use. Limitations include the lack of disease severity data and the absence of visits for newer therapies, such as Janus kinase inhibitors.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"73-75"},"PeriodicalIF":0.0,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry.","authors":"Liana Barenbrug, Renate G van der Molen, Jake S F Maurits, Marieke M B Seyger, Marisol E Otero, Antoni H Gostynski, Femke M Homan, Paul M Ossenkoppele, Inge M Haeck, Judith H J Hendricksen-Roelofzen, John E M Körver, Sharon R P Dodemont, Berit Velstra, Maartje A M Berends, Lizelotte J M T Weppner-Parren, Romy Keijsers, Annet M Oostveen, Bas Peters, Roland J M Mommers, Martijn B A van Doorn, Milan Tjioe, Peter W Arnold, Astrid L A Kuijpers, Marloes M Kleinpenning, Elke M G J de Jong, Juul M P A van den Reek","doi":"10.1177/24755303251327926","DOIUrl":"10.1177/24755303251327926","url":null,"abstract":"<p><strong>Background: </strong>Drug survival of biologics for psoriasis has reported to be lower in females than males for first-generation biologics (TNF-α/interleukin (IL) 12/23 inhibitors (i)); insights for newer biologics (IL17i and IL23i) are scarce.</p><p><strong>Objectives: </strong>To study sex-differences in drug survival and other treatment outcomes of biologics (including IL17i/IL23i) in patients with psoriasis.</p><p><strong>Methods: </strong>Data were obtained from the Dutch, prospective, multicenter, BioCAPTURE registry. Kaplan-Meier drug survival curves were split for specific discontinuation reasons and stratified for sex. Cox regression models with confounder correction were used to investigate the association of sex with drug survival. Adverse events (AEs) leading to biologic discontinuation were compared between sexes. Confounder-corrected Generalized Estimated Equation models were used to compare the course Psoriasis Area and Severity Index (PASI), Treatment Satisfaction Questionnaire for Medication (TSQM)) scores, and Dermatology Life Quality Index (DLQI) scores between sexes.</p><p><strong>Results: </strong>We included 428 females and 703 males (respectively 744 and 1069 treatment episodes). For all biologics, female sex was associated with shorter overall, AE-related, and effectiveness-related drug survival. For IL17i/IL23i specifically, female sex was associated with shorter overall and effectiveness-related drug survival, but not with shorter AE-related drug survival. In the TSQM females reported to experience more often AEs and to be, in general, less satisfied than males. No sex-differences were found for PASI and DLQI during the first year of treatment.</p><p><strong>Conclusion: </strong>Biologics, including IL17i and IL23i, showed lower drug survival rates for females. This could be linked to the sex-differences we found regarding AEs and treatment satisfaction with biologics<b>.</b></p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"91-100"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fatigue and the Impact of Musculoskeletal Pain on Quality of Life in Pediatric Patients With Psoriasis.","authors":"Thaís Cugler Meneghetti, Vânia Oliveira Carvalho, Luciana Martins de Carvalho, Virgínia Paes Leme Ferriani","doi":"10.1177/24755303251327940","DOIUrl":"10.1177/24755303251327940","url":null,"abstract":"<p><strong>Background and aims: </strong>Musculoskeletal pain associated to psoriasis without the presence of psoriatic arthritis is a poor explored issue in pediatric population. The aim of this study was to compare the health-related quality of life (HRQoL) and fatigue scores of pediatric patients with psoriasis and healthy peers and estimate the impact of musculoskeletal pain.</p><p><strong>Methods: </strong>The pediatric Gait Arms Legs and Spine (pGALS) questions were used to screen for musculoskeletal pain. General HRQoL was measured using the Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL 4.0) and fatigue was assessed using the PedsQL-Multidimensional Fatigue Scale (PedsQL-MFS).</p><p><strong>Results: </strong>Fifty psoriatic patients (12.1years old; IQR 9-15) and 50 controls (12.3 years old; IQR 8.8-15.9) were evaluated. Patients with psoriasis had long disease duration of 6.9 years (IQR 3.7-9.5) and predominantly low disease activity (PASI 3.2, IQR 0.8-6; BSA 3.0, IQR 1-8), mainly treated with topical therapy. The PedsQL 4.0 total score of psoriatic patients with musculoskeletal pain was poorer than controls with pain. Fatigue by PedsQL-MFS was also worse in patients with psoriasis and pain. The risk of impaired HRQoL was 7.7 times higher in the presence of musculoskeletal pain (OR = 7.71, 95%CI 1.66-35.78); other variables such as age, sex and severity of psoriasis did not increase the risk of HRQoL impairment.</p><p><strong>Conclusions: </strong>Musculoskeletal pain and fatigue may provide clues for systemic impairment in pediatric psoriatic disease and calls for effective systemic treatment to reduce disease burden and accumulated damage.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"84-90"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 Reviewer Thank You.","authors":"","doi":"10.1177/24755303251319674","DOIUrl":"https://doi.org/10.1177/24755303251319674","url":null,"abstract":"","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251319674"},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11800225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Chronic Generalized Pustular Psoriasis: A Review and Expert Opinion.","authors":"Boni Elewski, Mark G Lebwohl","doi":"10.1177/24755303251318976","DOIUrl":"10.1177/24755303251318976","url":null,"abstract":"<p><p><b>Introduction:</b> Generalized pustular psoriasis (GPP) is a rare, chronic inflammatory skin disease characterized by persistent symptoms and sudden flares of painful sterile pustules, sometimes accompanied by systemic inflammation. Patients with GPP experience chronic disease burden even when not experiencing flares. There is an unmet need for guidelines on continuous long-term management of this disease. <b>Areas Covered:</b> This review summarizes existing literature describing the chronic disease burden of GPP, the persistence of symptoms and effects on quality of life (QoL) when patients are not experiencing a flare, the recurring nature of GPP flares, and the high prevalence of chronic comorbidities. We also present an overview of results from the EFFISAYIL® 2 study, which was the first randomized, placebo-controlled clinical trial to systematically evaluate continuous management with subcutaneous spesolimab, a first-in-class anti-interleukin-36 receptor monoclonal antibody specifically designed to treat GPP. <b>Expert Opinion:</b> An unmet need in GPP is the establishment of guidelines for chronic disease management, including measures for treating GPP between flares, flare prevention, and long-term disease control. Treatment strategies should mitigate both the persistent disease burden and potentially life-threatening flare episodes. Intravenous spesolimab is currently the only FDA-approved medication to treat GPP flares, and subcutaneous spesolimab is the only FDA-approved medication to treat GPP when patients are not experiencing a flare. Guidelines should aim to advance the recognition of GPP as a chronic disease and emphasize prompt diagnosis and timely access to FDA-approved therapies according to the diagnostic criteria established by the International Psoriasis Council and the National Psoriasis Foundation.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"58-66"},"PeriodicalIF":0.0,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare Resource Utilization Among Patients With Generalized Pustular Psoriasis: The Impact of Flares and Disease Severity.","authors":"Megan H Noe, Layla Lavasani, Lawrence Rasouliyan, Marianne Laouri, Jamie L W Rhoads","doi":"10.1177/24755303251317193","DOIUrl":"10.1177/24755303251317193","url":null,"abstract":"<p><strong>Background: </strong>Generalized pustular psoriasis (GPP) is a rare, chronic, often unpredictable, severe multisystemic autoinflammatory skin disease from which patients can experience flares, episodes of widespread eruptions of painful, sterile pustules often accompanied by systemic symptoms. The impact of GPP flares and underlying GPP severity on the healthcare resource utilization (HCRU) is not well characterized.</p><p><strong>Objective: </strong>To quantify HCRU among US GPP patients by flare status and underlying severity.</p><p><strong>Methods: </strong>Outpatient electronic health record (EHR) data (2017-2023) from the OMNY Health platform were linked with claims. Patients were indexed at first EHR GPP diagnosis code and followed for 1 year. GPP flares were identified from a previously developed algorithm. All-cause hospitalizations, emergency department/urgent care (ED/UC), and outpatient visits were summarized by flare status and underlying severity. Pharmacy and total gross charges were described by number of flares.</p><p><strong>Results: </strong>A total of 335 patients were included. Patients who flared in the follow-up period (n = 205) had more hospitalizations than patients who did not flare (n = 130; 12.2% vs 6.9%; mean: 0.26 vs 0.09). ED/UC visits were similar between groups (22.9% vs 27.7%; mean: 0.54 vs 0.45), while outpatient visits were greater among patients who did not flare (69.8% vs 78.5%; mean: 5.37 vs 6.56). For patients with 0, 1, and ≥2 flares with HCRU, mean pharmacy charges ($19,887, $25,180, and $57,674, respectively) and total gross charges ($29,196, $40,079, and $52,940, respectively) increased monotonically.</p><p><strong>Conclusion: </strong>GPP patients who flared and had more severe disease had greater HCRU and charges.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"51-57"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America.","authors":"Bruce Strober, Yichen Zhong, Adam Sima, Alicia Beeghly, Thomas Eckmann, Eugene Balagula, Joe Zhuo, Mark Lebwohl","doi":"10.1177/24755303241302070","DOIUrl":"10.1177/24755303241302070","url":null,"abstract":"<p><strong>Background: </strong>The International Psoriasis Council (IPC) updated the classification of psoriasis severity to guide clinical decision-making. According to IPC guidelines, patients are considered candidates for systemic therapy when body surface area (BSA) is >10%, when lesions affect special body areas (ie, face, palms, soles, genitals, scalp, or nails), or when topical therapy fails to control symptoms.</p><p><strong>Objective: </strong>To evaluate patient candidacy for systemic therapy in real-world settings, according to disease severity criteria.</p><p><strong>Methods: </strong>This cross-sectional study included systemic treatment-naive patients from the CorEvitas Psoriasis Registry who initiated systemic treatment at Registry visits between April 2015 and April 2023. Based on IPC criteria, systemic therapy candidates were identified, and data on demographics and clinical characteristics, including disease severity indicators (ie, BSA and Psoriasis Area Severity Index [PASI] scores) and patient-reported outcome measures, were collected and descriptively summarized.</p><p><strong>Results: </strong>The analysis included 2739 systemic therapy initiators with plaque psoriasis, of whom 82.7% met IPC criteria for systemic therapy. Of the 2265 systemic therapy candidates, 56.2% had a BSA >10%, 53.2% had a history of psoriasis affecting special areas, and 55.2% had prior but not current use of topical therapy. Notably, 71.0% of candidates for systemic therapy had PASI scores ≤12.</p><p><strong>Conclusion: </strong>In this large real-world study, most patients with psoriasis who initiated systemic therapy met the IPC disease severity criteria to do so. Disease severity categorization based on PASI scores and BSA percentage alone may not adequately capture all patients who might be candidates for systemic psoriasis treatment.</p><p><strong>Clinicaltrialsgov: </strong>NCT02707341.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"22-27"},"PeriodicalIF":0.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}